Abstract
Pseudomonas aeruginosa is a common pathogen that is responsible for serious hospital-acquired infections, ventilator-associated pneumonia, and various sepsis syndromes. Also, it is a multidrug-resistant pathogen recognized for its ubiquity and its intrinsically advanced antibiotic-resistant mechanisms. It usually affects immunocompromised individuals but can also infect immunocompetent individuals. There is no vaccine against it available till now. This study predicts an effective epitope-based vaccine against fructose bisphosphate aldolase (FBA) of Pseudomonas aeruginosa using immunoinformatics tools. The protein sequences were obtained from NCBI, and prediction tests were undertaken to analyze possible epitopes for B and T cells. Three B cell epitopes passed the antigenicity, accessibility, and hydrophilicity tests. Six MHC I epitopes were found to be promising, while four MHC II epitopes were found promising from the result set. Nineteen epitopes were shared between MHC I and II results. For the population coverage, the epitopes covered 95.62% worldwide excluding certain MHC II alleles. We recommend in vivo and in vitro studies to prove its effectiveness.
Highlights
Pseudomonas aeruginosa is a motile, nonfermenting, gramnegative opportunistic bacterium that is implicated in respiratory infections, urinary tract infections, gastrointestinal infections, keratitis, otitis media, and bacteremia in patients with compromised host defences [1]
P. aeruginosa is responsible for millions of infections each year in the community, 10–15% of all healthcare-associated infections, with more than 300,000 cases annually in the EU, USA, and Japan [5]
A total of 20,201 strains of Pseudomonas aeruginosa fructose bisphosphate aldolase (FBA) were retrieved in FASTA for
Summary
Pseudomonas aeruginosa is a motile, nonfermenting, gramnegative opportunistic bacterium that is implicated in respiratory infections, urinary tract infections, gastrointestinal infections, keratitis, otitis media, and bacteremia in patients with compromised host defences (e.g., cancer, burn, HIV, and cystic fibrosis) [1]. Intensive care unit (ICU) hospitalized patients constitute one of the risk groups that are more susceptible to acquire pseudomonas infections as they may develop ventilator-associated pneumonia (VAP) and sepsis [2,3,4]. This organism is a ubiquitous and metabolically versatile microbe that flourishes in many environments and possesses many virulence factors that contribute to its pathogenesis [1]. It is a common nosocomial pathogen [6, 7] that causes infections with a high mortality rate [8, 9] which is attributable to the organism that possesses an intrinsic resistance to many antimicrobial agents [10] and the development of increased, multidrug resistance in healthcare settings [11,12,13], both of which
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
